Parkman Healthcare Partners’s Stereotaxis STXS Stock Holding History

Parkman Healthcare Partners’s Portfolio STXS Stock Details STXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-413,218	Closed	-$2.56M	–	93
2021 Q4	$2.56M	Sell	413,218 -36,782	-8%	-$220K	0.57%	47
2021 Q3	$2.42M	Sell	450,000 -229,082	-34%	-$1.73M	0.61%	51
2021 Q2	$6.55M	Buy	679,082 +3,160	+0.5%	+$24.9K	1.43%	25
2021 Q1	$4.54M	Buy	675,922 +28,379	+4%	+$168K	1.05%	33
2020 Q4	$3.3M	Buy	647,543 +3,730	+0.6%	+$15.3K	0.84%	45
2020 Q3	$2.31M	Sell	643,813 -24,880	-4%	-$95.9K	0.61%	55
2020 Q2	$2.98M	Buy	668,693 +15,000	+2%	+$60.7K	0.84%	43
2020 Q1	$1.97M	Buy	653,693 +121,975	+23%	+$504K	0.91%	39
2019 Q4	$2.81M	Buy	+531,718	New	+$2.11M	0.81%	43

Other funds holding STXS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

ITP

Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's STXS Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of Stereotaxis (STXS) in Q1 2022, closing a stake of 413,218 shares — an estimated $2.56M sold.

Parkman Healthcare Partners first reported a position in STXS in Q4 2019 and held it in 9 quarters. The position peaked at $6.55M in Q2 2021. 93 funds tracked by Wall St. Rank hold STXS as of Q1 2022.

Parkman Healthcare Partners reported no remaining Stereotaxis position as of Q1 2022 after selling out during the quarter.
Parkman Healthcare Partners sold 413,218 Stereotaxis shares in Q1 2022, an estimated $2.56M.
Parkman Healthcare Partners first reported a position in Stereotaxis in Q4 2019 and held it in 9 quarters.
Parkman Healthcare Partners's Stereotaxis position peaked at $6.55M in Q2 2021.
93 funds tracked by Wall St. Rank held Stereotaxis as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.